Monobodies and nanobodies: The era of diagnostic miniature antibodies
Keywords:Monobodies, nanabodies, Fibronectin, targeted therapy, drug like properties
Monobodies, as the name suggests, are the simplest synthetic version of antibodies engineered to mimic antibodies (antibody mimetics) without their complexity. These are constructed using a fibronectin type III domain (FN3) as a molecular scaffold. With a molecular mass of not more than 20 kDA at max, monobodies are excellent tools for in-vivo diagnosis. Unlike the conventional Ab that needs particular treatment protocols to enable them to enter into cells, mono, and nano bodies can be expressed inside the cells with expression cassettes. With high affinity and selectivity, mono and nanobodies can be developed in the shortest possible time with ease that otherwise can't be done by conventional antibodies. Produced from combinatorial libraries and diversified using phage display techniques, monobodies can be generated that are highly specific for their intracellular targets, like monobodies to detect COVID antigens. Similarly, monobodies against KRAS mutants using protein engineering technologies can be sued to detect mutant KRAS in solid tumors. They have a strong tendency to bind to functional sites of specific intracellular target proteins and thus exhibits drug-like properties as well as specific `inhibitors. Monobodies are evolving with additional diverse functions and may soon be used as am indispensable tool in biology and medicine.
- 2023-10-02 (2)
- 2023-10-02 (1)
How to Cite
Copyright (c) 2023 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).